Search Legislation

The Patents (Amendment) (EU Exit) Regulations 2019

 Help about what version

What Version

 Help about advanced features

Advanced Features

 Help about opening options

Opening Options

Changes over time for: PART 7

 Help about opening options

Alternative versions:

Changes to legislation:

There are currently no known outstanding effects for the The Patents (Amendment) (EU Exit) Regulations 2019, PART 7. Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.

PART 7U.K.COMPULSORY LICENSING OF PHARMACEUTICAL PATENTS - AMENDMENTS TO REGULATION (EC) NO 816/2006

37.  Regulation (EC) No 816/2006 of the European Parliament and of the Council of 17 May 2006 on compulsory licensing of patents relating to the manufacture of pharmaceutical products for export to countries with public health problems is amended as set out in this Part.

Commencement Information

I1Reg. 37 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

38.—(1) Article 1 (scope) is amended as follows.

(2) For “Member States”, substitute “ The competent authority ”.

Commencement Information

I2Reg. 38 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

39.—(1) Article 2 (definitions) is amended as follows.

(2) For the definition of “competent authority” in paragraph (4), substitute—

competent authority” for the purposes of Articles 1 to 11, 16 and 17 means the Comptroller-General of Patents, Designs and Trade Marks;.

(3) After paragraph (4), insert—

(5) patent” means “a patent under the Patents Act 1977;

(6) supplementary protection certificate” means a supplementary protection certificate issued under Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products.

(4) Omit Article 3 (competent authority).

Commencement Information

I3Reg. 39 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

40.  In Article 4 (eligible importing countries), for “Commission”, substitute “ United Kingdom ”.

Commencement Information

I4Reg. 40 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

41.—(1) Article 5 (extension to least-developed and developing countries which are not members of the WTO) is amended as follows.

(2) In paragraph (a), for “Commission”, substitute “ Secretary of State ”.

(3) In paragraph (c), omit “or on its own initiative if national law allows the competent authority to act on its own initiative,”.

Commencement Information

I5Reg. 41 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

42.—(1) Article 6 (application for a compulsory licence) is amended as follows.

(2) For paragraph 1, substitute—

1.  Any person may submit an application for a compulsory licence under this Regulation to the competent authority in a case where that person's intended activities of manufacture and sale for export are covered by a patent or a supplementary protection certificate..

(3) In paragraph 2, for “each application”, substitute “ the application made to the competent authority ”.

(4) Omit paragraph 4.

Commencement Information

I6Reg. 42 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

43.  In Article 8 (verification), for “Commission”, wherever it occurs, substitute “ United Kingdom ”.

Commencement Information

I7Reg. 43 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

44.—(1) Article 10 (compulsory licence conditions) is amended as follows.

(2) In paragraph 5, for “Member States”, substitute “ United Kingdom ”.

(3) In paragraph 8, omit “or on its own initiative, if national law allows the competent authority to act on its own initiative.”.

Commencement Information

I8Reg. 44 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

45.—(1) Article 12 (notification) is amended as follows.

(2) For “Member State”, substitute “ Secretary of State ”.

(3) Omit “through the intermediary of the Commission”.

Commencement Information

I9Reg. 45 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

46.  In Article 13 (prohibition of importation), in paragraph 1, for “Community”, substitute “ United Kingdom ”.

Commencement Information

I10Reg. 46 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

47.—(1) Article 14 (action by customs authorities) is amended as follows.

(2) In paragraph 1—

(a)for “Community” substitute “ United Kingdom ”; and

(b)omit “Member States shall ensure that a body has the authority to review whether such importation is taking place”.

(3) In paragraph 2, for “national provisions on”, substitute “ the law relating to ”.

(4) In paragraph 3, for “Community”, substitute “ United Kingdom ”.

(5) In paragraph 4, omit “, in accordance with national legislation,”.

(6) Omit paragraph 6.

Commencement Information

I11Reg. 47 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

48.—(1) Article 16 (termination or review of the licence) is amended as follows.

(2) In paragraph 2, for “through the intermediary of the Commission”, substitute “ by the Secretary of State ”.

(3) In paragraph 3, omit—

(a)“or any other body appointed by the Member State”; and

(b)“or by another body appointed by the Member State,”.

Commencement Information

I12Reg. 48 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

49.  Omit Articles 17 to 19. (appeals, safety and efficacy of medicinal products and review)

Commencement Information

I13Reg. 49 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

50.  After Article 20 (entry into force), omit “This Regulation shall be binding in its entirety and directly applicable in all Member States”.

Commencement Information

I14Reg. 50 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

Back to top

Options/Help

Print Options

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.

Close

See additional information alongside the content

Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.

Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

Explanatory Memorandum

Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as enacted version that was used for the print copy
  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources
Close

Timeline of Changes

This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.

Close

More Resources

Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as made version that was used for the print copy
  • correction slips

Click 'View More' or select 'More Resources' tab for additional information including:

  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • links to related legislation and further information resources